US life sciences company Bio-Techne Corporation (NASDAQ: TECH) announced on Thursday that its spatial biology brand, Lunaphore, is partnering with Discovery Life Sciences (Discovery) to add Lunaphore COMET, a best-in-class spatial biology platform, to Discovery's global suite of biospecimen products and specialty lab services supporting customers with clinical research.

The partnership utilises Lunaphore's COMET technology, a fully-automated, high-throughput, hyperplex platform with tissue profiling capabilities, with Discovery's scientific expertise with the aim of advancing immuno-oncology, immunology, neuroscience and infectious disease research across all development stages at a new level of precision and speed.

Discovery says that its Lunaphore COMET Hyperplex Immunofluorescence Services will facilitate the development of next-generation assays for clinical trials and provide multidimensional spatial biology insights to advance biomarker discovery, patient stratification and translational medicine.

Discovery CEO Greg Herrema, said: "We are excited to expand our specialty lab services offering to include Lunaphore COMET Hyperplex Immunofluorescence Services. By integrating COMET with Discovery's molecular pathology expertise, this partnership is poised to drive biomedical research breakthroughs. This new service combined with our rigorous regulatory compliance processes will provide pharmaceutical companies with the ability to develop Clinical Laboratory Improvement Amendment (CLIA) compliant hyperplex tests."